The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.
Roche also announced first-quarter sales shrank 1%.
A London court knocked down two Roche/Genentech patents, making a clearer path for biosimilars of the breast cancer drug. The primary patent lapses in July.
The FDA issued an official halt, five days after Halozyme stopped the Phase-II trial because of patient stroke information.
Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.
Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.
A court granted Lilly six more years of patent protection for the almost $3-billion-dollar-a-year cancer drug.
The company said it wants to wait for more data to come in.
The professional association says it's necessary, because high prices do not indicate impact.
The UK's National Institute for Health and Care Excellence says it bounced Bayer's drug for failing to compare itself to current treatments, and Sanofi's over cost.
The company says it will continue to test its MAGE-A3 cancer drug among a subset of non-small cell lung cancer patients and among melanoma patients.
Astellas and Medivation have applied for a pre-chemo indication for the cancer drug.
A working group set out parameters for what counts as a meaningful outcome for pancreatic, breast, lung and colon cancer clinical trials.
Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.
The drugmaker announced Tuesday that it will pursue a Phase-III Yervoy-nivolumab study.
A pilot program including mailed colon-cancer screening tests increased use of the tests among under-served patients.
Adding Avastin to chemotherapy added four months of survival, data show.
The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.
The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.
The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.
The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.
Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.
A court in India ruled biosimilar drug makers will not be able to cite the drug's name, efficacy or safety profile in its marketing.
The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.
The proposed solutions include education, access and low-cost interventions.
The company said in a statement that it is talking with the FDA about next steps. Data on overall survival—a key metric for how oncologists view new cancer meds—remains under wraps.
The two will explore cancer-attacking nanobodies.
New research finds overlap with some forms of breast, lung, and head & neck cancers, as well as 32 recurring genetic mutations.
The drug maker is kicking in $5 million—or 20% of funding—for the research "dream team," which is part of an alliance between Stand Up and the American Cancer Society.
A clinical trial shows that using Xtandi before chemotherapy—Zytiga's indication—improves progression-free survival.